- Home
- RBOT vs ANL Comparison
RBOT vs ANL Comparison
Compare RBOT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RBOT | ANL |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RBOT | ANL |
|---|---|---|
| Price | $3.11 | $1.38 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 133.8K | 10.1K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $1.10 |
| 52 Week High | $19.00 | $2.99 |
Technical Indicators
Market Signals| Indicator | RBOT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 32.63 |
| Support Level | $2.54 | $1.32 |
| Resistance Level | $3.66 | $1.59 |
| Average True Range (ATR) | 0.39 | 0.14 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 48.83 | 12.50 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.